Is adjuvant immunotherapy necessary after neoadjuvant chemoimmunotherapy in patients with resectable stage III NSCLC? A two-center real-world study

Is adjuvant immunotherapy necessary after neoadjuvant chemoimmunotherapy in patients with resectable stage III NSCLC? A two-center real-world study

Abstract Purpose The value of adjuvant immunotherapy in patients with resectable stage III non-small cell lung cancer (NSCLC) after neoadjuvant chemoimmunotherapy remains unclear. This study aimed to evaluate the prognostic impact of additional adjuvant immunotherapy in patients with stage III NSCLC...

Full description

Saved in:
Bibliographic Details
Main Authors: Song Guan, Hui Wang, Zhaoxin Chen, Fengrui Guo, Guozhen Yi, Xingyu Du, Jingjing Yan, Cuimeng Tian
Format: Article
Language:English
Published: Springer 2025-07-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Adjuvant immunotherapy
Neoadjuvant chemoimmunotherapy
Non-small cell lung cancer
Surgery
Online Access:https://doi.org/10.1007/s00262-025-04130-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items